Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 8/2015

01-08-2015 | Research Article

Transcriptome meta-analysis reveals dysregulated pathways in nasopharyngeal carcinoma

Authors: Warut Tulalamba, Noppadol Larbcharoensub, Ekaphop Sirachainan, Aunchalee Tantiwetrueangdet, Tavan Janvilisri

Published in: Tumor Biology | Issue 8/2015

Login to get access

Abstract

Nasopharyngeal carcinoma (NPC) is a malignant cancer arising from the epithelial surface of the nasopharynx that mostly appears in advanced stages of the disease, leading to a poor prognosis. To date, a number of mRNA profiling investigations on NPC have been reported in order to identify suitable biomarkers for early detection. However, the results may be specific to each study with distinct sample types. In this study, an integrative meta-analysis of NPC transcriptome data was performed to determine dysregulated pathways, potentially leading to identification of molecular markers. Ten independent NPC gene expression profiling microarray datasets, including 135 samples from NPC cell lines, primary cell lines, and tissues were assimilated into a meta-analysis and cross-validation to identify a cohort of genes that were significantly dysregulated in NPC. Bioinformatics analyses of these genes revealed the significant pathways and individual players involving in cellular metabolism, cell cycle regulation, DNA repair, as well as ErbB pathway. Altogether, we propose that dysregulation of these molecular pathways in NPC might play a role in the NPC pathogenesis, providing clues, which could eventually translate into diagnostic and therapeutic approaches.
Appendix
Available only for authorised users
Literature
1.
Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1765–77.PubMedCrossRef
2.
Chan AS, To KF, Lo KW, Mak KF, Pak W, Chiu B, et al. High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. Cancer Res. 2000;60(19):5365–70.PubMed
3.
4.
Li YH, Hu CF, Shao Q, Huang MY, Hou JH, Xie D, et al. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Transl Med. 2008;6:1.PubMedPubMedCentralCrossRef
5.
Wang HY, Zhang M, He PC, Yang BJ, Shao LY, Shao WB. Changes of gene expression profile in human myeloma cell line induced by thalidomide. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010;18(2):396–402.PubMed
6.
Janvilisri T. Omics-based identification of biomarkers for nasopharyngeal carcinoma. Dis Markers. Under review.
7.
Lin DC, Meng X, Hazawa M, Nagata Y, Varela AM, Xu L, et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet. 2014;46(8):866–71.PubMedCrossRef
8.
Hui AB, Lo KW, Teo PM, To KF, Huang DP. Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization. Int J Oncol. 2002;20(3):467–73.PubMed
9.
Zeng Z, Zhou Y, Xiong W, Luo X, Zhang W, Li X, et al. Analysis of gene expression identifies candidate molecular markers in nasopharyngeal carcinoma using microdissection and cDNA microarray. J Cancer Res Clin Oncol. 2007;133(2):71–81.PubMedCrossRef
10.
Zeng ZY, Zhou YH, Zhang WL, Xiong W, Fan SQ, Li XL, et al. Gene expression profiling of nasopharyngeal carcinoma reveals the abnormally regulated Wnt signaling pathway. Hum Pathol. 2007;38(1):120–33.PubMedCrossRef
11.
Lo PH, Xie D, Chan KC, Xu FP, Kuzmin I, Lerman MI, et al. Reduced expression of RASSF1A in esophageal and nasopharyngeal carcinomas significantly correlates with tumor stage. Cancer Lett. 2007;257(2):199–205.PubMedCrossRef
12.
Lung HL, Cheung AK, Xie D, Cheng Y, Kwong FM, Murakami Y, et al. TSLC1 is a tumor suppressor gene associated with metastasis in nasopharyngeal carcinoma. Cancer Res. 2006;66(19):9385–92.PubMedCrossRef
13.
Chen X, Liang S, Zheng W, Liao Z, Shang T, Ma W. Meta-analysis of nasopharyngeal carcinoma microarray data explores mechanism of EBV-regulated neoplastic transformation. BMC Genomics. 2008;9:322.PubMedPubMedCentralCrossRef
14.
Lee YC, Hwang YC, Chen KC, Lin YS, Huang DY, Huang TW, et al. Effect of Epstein-Barr virus infection on global gene expression in nasopharyngeal carcinoma. Funct Integr Genomics. 2007;7(1):79–93.PubMedCrossRef
15.
Chang JT, Chan SH, Lin CY, Lin TY, Wang HM, Liao CT, et al. Differentially expressed genes in radioresistant nasopharyngeal cancer cells: gp96 and GDF15. Mol Cancer Ther. 2007;6(8):2271–9.PubMedCrossRef
16.
Guo Y, Chen JX, Yang S, Fu XP, Zhang Z, Chen KH, et al. Selection of reliable reference genes for gene expression study in nasopharyngeal carcinoma. Acta Pharmacol Sin. 2010;31(11):1487–94.PubMedPubMedCentralCrossRef
17.
Sengupta S, den Boon JA, Chen IH, Newton MA, Dahl DB, Chen M, et al. Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res. 2006;66(16):7999–8006.PubMedCrossRef
18.
Dodd LE, Sengupta S, Chen IH, den Boon JA, Cheng YJ, Westra W, et al. Genes involved in DNA repair and nitrosamine metabolism and those located on chromosome 14q32 are dysregulated in nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2216–25.PubMedCrossRef
19.
Bose S, Yap LF, Fung M, Starzcynski J, Saleh A, Morgan S, et al. The ATM tumour suppressor gene is down-regulated in EBV-associated nasopharyngeal carcinoma. J Pathol. 2009;217(3):345–52.PubMedCrossRef
20.
Liu SC, Jen YM, Jiang SS, Chang JL, Hsiung CA, Wang CH, et al. G(alpha)12-mediated pathway promotes invasiveness of nasopharyngeal carcinoma by modulating actin cytoskeleton reorganization. Cancer Res. 2009;69(15):6122–30.PubMedCrossRef
21.
Li J, Fan Y, Chen J, Yao KT, Huang ZX. Microarray analysis of differentially expressed genes between nasopharyngeal carcinoma cell lines 5-8F and 6-10B. Cancer Genet Cytogenet. 2010;196(1):23–30.PubMedCrossRef
22.
Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19(2):185–93.PubMedCrossRef
23.
Diehn M, Sherlock G, Binkley G, Jin H, Matese JC, Hernandez-Boussard T, et al. SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Res. 2003;31(1):219–23.PubMedPubMedCentralCrossRef
24.
Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003;34(2):374–8.PubMed
25.
Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 2005;33(Web Server issue):W741-8.PubMed
26.
Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, et al. STRING 8—a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 2009;37(Database issue):D412–6.PubMedCrossRef
27.
Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Exp Rev Mol Med. 2007;9(12):1–24.CrossRef
28.
Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002;20(8):2038–44.PubMedCrossRef
29.
Chow WH, Gridley G, Fraumeni Jr JF, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343(18):1305–11.PubMedCrossRef
30.
Foufelle F, Girard J, Ferre P. Regulation of lipogenic enzyme expression by glucose in liver and adipose tissue: a review of the potential cellular and molecular mechanisms. Adv Enzyme Regul. 1996;36:199–226.PubMedCrossRef
31.
Bustamante E, Morris HP, Pedersen PL. Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. J Biol Chem. 1981;256(16):8699–704.PubMed
32.
Thomassen M, Tan Q, Kruse TA. Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer. BMC Cancer. 2008;8:394.PubMedPubMedCentralCrossRef
33.
Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005;90(2):105–12.PubMedCrossRef
34.
Stewart ZA, Westfall MD, Pietenpol JA. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci. 2003;24(3):139–45.PubMedCrossRef
35.
Deshpande A, Sicinski P, Hinds PW. Cyclins and cdks in development and cancer: a perspective. Oncogene. 2005;24(17):2909–15.PubMedCrossRef
36.
Kuo CL, Wu SY, Ip SW, Wu PP, Yu CS, Yang JS, et al. Apoptotic death in curcumin-treated NPC-TW 076 human nasopharyngeal carcinoma cells is mediated through the ROS, mitochondrial depolarization and caspase-3-dependent signaling responses. Int J Oncol. 2011;39(2):319–28.PubMed
37.
Huang SY, Hsieh MJ, Chen CY, Chen YJ, Chen JY, Chen MR, et al. Epstein-Barr virus Rta-mediated transactivation of p21 and 14-3-3sigma arrests cells at the G1/S transition by reducing cyclin E/CDK2 activity. J Gen Virol. 2012;93(Pt 1):139–49.PubMedCrossRef
38.
Huang C, Tang H, Zhang W, She X, Liao Q, Li X, et al. Integrated analysis of multiple gene expression profiling datasets revealed novel gene signatures and molecular markers in nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2012;21(1):166–75.PubMedCrossRef
39.
Shaltiel IA, Krenning L, Bruinsma W, Medema RH. The same, only different—DNA damage checkpoints and their reversal throughout the cell cycle. J Cell Sci. 2015;128(4):607–20.PubMedCrossRef
40.
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365(9460):671–9.PubMedCrossRef
41.
Lee SW, Chen TJ, Lin LC, Li CF, Chen LT, Hsing CH, et al. Overexpression of thymidylate synthetase confers an independent prognostic indicator in nasopharyngeal carcinoma. Exp Mol Pathol. 2013;95(1):83–90.PubMedCrossRef
42.
Cardoso F, Ross JS, Picart MJ, Sotiriou C, Durbecq V. Targeting the ubiquitin-proteasome pathway in breast cancer. Clin Breast Cancer. 2004;5(2):148–57.PubMedCrossRef
43.
Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009;21(2):177–84.PubMedCrossRef
44.
Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24(17):2666–72.PubMedCrossRef
45.
Uberall I, Kolar Z, Trojanec R, Berkovcova J, Hajduch M. The status and role of ErbB receptors in human cancer. Exp Mol Pathol. 2008;84(2):79–89.PubMedCrossRef
46.
Cao XJ, Hao JF, Yang XH, Xie P, Liu LP, Yao CP, et al. Prognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinoma. Med Oncol. 2012;29(1):263–71.PubMedCrossRef
47.
Kim YJ, Go H, Wu HG, Jeon YK, Park SW, Lee SH. Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy. Head Neck. 2011;33(10):1458–66.PubMedCrossRef
48.
Kim TJ, Lee YS, Kang JH, Kim YS, Kang CS. Prognostic significance of expression of VEGF and Cox-2 in nasopharyngeal carcinoma and its association with expression of C-erbB2 and EGFR. J Surg Oncol. 2011;103(1):46–52.PubMedCrossRef
49.
Roychowdhury DF, Tseng Jr A, Fu KK, Weinburg V, Weidner N. New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression. Cancer. 1996;77(8):1419–26.PubMedCrossRef
50.
Yazici H, Altun M, Alatli C, Dogan O, Dalay N. c-erbB-2 gene amplification in nasopharyngeal carcinoma. Cancer Invest. 2000;18(1):6–10.PubMedCrossRef
51.
Yan J, Fang Y, Huang BJ, Liang QW, Wu QL, Zeng YX. Absence of evidence for HER2 amplification in nasopharyngeal carcinoma. Cancer Genet Cytogenet. 2002;132(2):116–9.PubMedCrossRef
52.
Lui VW, Lau CP, Ho K, Ng MH, Cheng SH, Tsao SW, et al. Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells. Invest New Drugs. 2011;29(6):1241–52.PubMedCrossRef
53.
Zhang Y, Liang G, Sun G, Pan Z, Wu G, Liu Z. Expression of C-erbB-2 and EGFR expression and its relationship with cell proliferation in nasopharyngeal carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011;25(2):67–70.PubMed
54.
Shnayder Y, Kuriakose MA, Yee H, Chen FA, DeLacure MD, Xue XN, et al. Adhesion molecules as prognostic factors in nasopharyngeal carcinoma. Laryngoscope. 2001;111(10):1842–6.PubMedCrossRef
55.
Bar-Sela G, Kuten A, Ben-Eliezer S, Gov-Ari E, Ben-Izhak O. Expression of HER2 and C-KIT in nasopharyngeal carcinoma: implications for a new therapeutic approach. Mod Pathol. 2003;16(10):1035–40.PubMedCrossRef
56.
Tulalamba W, Larbcharoensub N, Janvilisri T. ERBB3 as an independent prognostic marker for nasopharyngeal carcinoma. J Clin Pathol. 2014;67(8):667–72.PubMedCrossRef
57.
Liu JY, Chuang TC, Way TD, Tsai TC, Hu CL, Liu GY, et al. The N-terminal domain of EBNA1 acts as a suppressor of the HER2/neu oncogene. Cancer Lett. 2009;273(2):273–80.PubMedCrossRef
58.
Lee SC, Lim SG, Soo R, Hsieh WS, Guo JY, Putti T, et al. Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. Pharmacogenet Genomics. 2006;16(1):73–4.PubMedCrossRef
59.
Eccles SA. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol. 2011;55(7–9):685–96.PubMedCrossRef
60.
Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Ann Rev Pharm Toxicol. 2004;44:195–217.PubMedCrossRef
61.
62.
Kumar R, Gururaj AE, Barnes CJ. p21-activated kinases in cancer. Nat Rev Cancer. 2006;6(6):459–71.PubMedCrossRef
63.
Armstrong DK, Kaufmann SH, Ottaviano YL, Furuya Y, Buckley JA, Isaacs JT, et al. Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res. 1994;54(20):5280–3.PubMed
64.
Ma S, Yang Y, Wang C, Hui N, Gu L, Zhong H, et al. Endogenous human CaMKII inhibitory protein suppresses tumor growth by inducing cell cycle arrest and apoptosis through down-regulation of the phosphatidylinositide 3-kinase/Akt/HDM2 pathway. J Biol Chem. 2009;284(37):24773–82.PubMedPubMedCentralCrossRef
Metadata
Title
Transcriptome meta-analysis reveals dysregulated pathways in nasopharyngeal carcinoma
Authors
Warut Tulalamba
Noppadol Larbcharoensub
Ekaphop Sirachainan
Aunchalee Tantiwetrueangdet
Tavan Janvilisri
Publication date
01-08-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 8/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3268-7

Other articles of this Issue 8/2015

Tumor Biology 8/2015 Go to the issue

Research Article

N-Acetyltransferase 2 (NAT2) polymorphism as a risk modifier of susceptibility to pediatric acute lymphoblastic leukemia

Research Article

A study on oncogenic role of leptin and leptin receptor in oral squamous cell

Research Article

Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12

Research Article

Genetic variability of glutathione S-transferases influences treatment outcome of breast cancer

Research Article

The role of tumor suppressor gene SOX11 in prostate cancer

Research Article

DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits